Biotalys N.V [BTLS] vs Syneos Health [SYENS] Detailed Stock Comparison
Biotalys N.V
Euronext
Loading...
Syneos Health
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Biotalys N.V wins in 6 metrics, Syneos Health wins in 9 metrics, with 0 ties. Syneos Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biotalys N.V | Syneos Health | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | 377.86 | N/A |
| Price-to-Book Ratio | 6.59 | 1.20 | Syneos Health |
| Debt-to-Equity Ratio | 17.56 | 45.57 | Biotalys N.V |
| PEG Ratio | -12.15 | 9.75 | Biotalys N.V |
| EV/EBITDA | -13.13 | 7.67 | Biotalys N.V |
| Profit Margin (TTM) | 0.00% | -1.30% | Biotalys N.V |
| Operating Margin (TTM) | -217.37% | 10.86% | Syneos Health |
| EBITDA Margin (TTM) | N/A | 10.86% | N/A |
| Return on Equity | -49.60% | -1.20% | Syneos Health |
| Return on Assets (TTM) | -23.00% | 3.16% | Syneos Health |
| Free Cash Flow (TTM) | $-12.79M | $217.00M | Syneos Health |
| 1-Year Return | 62.84% | 12.17% | Biotalys N.V |
| Price-to-Sales Ratio (TTM) | 57.29 | 1.11 | Syneos Health |
| Enterprise Value | $162.07M | $9.11B | Syneos Health |
| EV/Revenue Ratio | 50.92 | 1.37 | Syneos Health |
| Gross Profit Margin (TTM) | N/A | 30.87% | N/A |
| Revenue per Share (TTM) | $0 | $64 | Syneos Health |
| Earnings per Share (Diluted) | $-0.40 | $-0.81 | Biotalys N.V |
| Beta (Stock Volatility) | 0.97 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biotalys N.V vs Syneos Health Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biotalys N.V | 0.42% | 8.31% | -3.98% | 53.02% | 34.64% | 37.71% |
| Syneos Health | 0.98% | 10.13% | 13.46% | 22.32% | -2.41% | 11.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biotalys N.V | 62.84% | -32.30% | -31.14% | -31.14% | -31.14% | -31.14% |
| Syneos Health | 12.17% | -17.42% | -17.42% | -17.42% | -17.42% | -17.42% |
Performance & Financial Health Analysis: Biotalys N.V vs Syneos Health
| Metric | BTLS | SYENS |
|---|---|---|
| Market Information | ||
| Market Cap | €182.34M | €7.41B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 30,116 | 125,453 |
| 90 Day Avg. Volume | 33,538 | 108,465 |
| Last Close | €4.82 | €78.04 |
| 52 Week Range | €2.51 - €5.50 | €53.70 - €84.85 |
| % from 52W High | -12.36% | -8.03% |
| All-Time High | €7.98 (Jun 28, 2021) | €109.90 (Dec 11, 2023) |
| % from All-Time High | -39.60% | -28.99% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.08% |
| Quarterly Earnings Growth | N/A | 0.72% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.01% |
| Operating Margin (TTM) | -2.17% | 0.11% |
| Return on Equity (TTM) | -0.50% | -0.01% |
| Debt to Equity (MRQ) | 17.56 | 45.57 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €0.74 | €60.47 |
| Cash per Share (MRQ) | €0.60 | €12.85 |
| Operating Cash Flow (TTM) | €-12,651,000 | €749.00M |
| Levered Free Cash Flow (TTM) | €-7,145,625 | €451.50M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Biotalys N.V vs Syneos Health
| Metric | BTLS | SYENS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 377.86 |
| Forward P/E | -12.15 | 9.75 |
| PEG Ratio | -12.15 | 9.75 |
| Price to Sales (TTM) | 57.29 | 1.11 |
| Price to Book (MRQ) | 6.59 | 1.20 |
| Market Capitalization | ||
| Market Capitalization | €182.34M | €7.41B |
| Enterprise Value | €162.07M | €9.11B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 50.92 | 1.37 |
| Enterprise to EBITDA | -13.13 | 7.67 |
| Risk & Other Metrics | ||
| Beta | 0.97 | N/A |
| Book Value per Share (MRQ) | €0.74 | €60.47 |
Financial Statements Comparison: Biotalys N.V vs Syneos Health
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BTLS | SYENS |
|---|---|---|
| Revenue/Sales | €0 | €1.68B |
| Cost of Goods Sold | N/A | €1.16B |
| Gross Profit | N/A | €514.00M |
| Research & Development | €3.47M | €78.00M |
| Operating Income (EBIT) | €-4.39M | €147.00M |
| EBITDA | €-2.99M | €306.00M |
| Pre-Tax Income | €-3.47M | €29.00M |
| Income Tax | €3,000 | €27.00M |
| Net Income (Profit) | €-3.47M | €2.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BTLS | SYENS |
|---|---|---|
| Cash & Equivalents | €22.64M | €579.00M |
| Total Current Assets | €26.24M | €3.28B |
| Total Current Liabilities | €4.77M | €2.07B |
| Long-Term Debt | €3.69M | €1.77B |
| Total Shareholders Equity | €27.61M | €7.27B |
| Retained Earnings | €-11.72M | €4.77B |
| Property, Plant & Equipment | €7.04M | €3.85B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BTLS | SYENS |
|---|---|---|
| Operating Cash Flow | €-4.09M | €40.00M |
| Capital Expenditures | €-93,000 | €-143.00M |
| Free Cash Flow | €-2.44M | €9.00M |
| Debt Repayment | N/A | €-166.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BTLS | SYENS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 30,116 | 125,453 |
| Average Daily Volume (90 Day) | 33,538 | 108,465 |
| Shares Outstanding | 37.46M | 103.45M |
| Float Shares | 13.32M | 69.85M |
| % Held by Insiders | 0.48% | 0.31% |
| % Held by Institutions | 0.22% | 0.28% |
Dividend Analysis & Yield Comparison: Biotalys N.V vs Syneos Health
| Metric | BTLS | SYENS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |